Aetiologies and temporal trends of atrioventricular block in young patients: a 20-year nationwide study

Johnni Rudbeck-Resdal, Morten K Christiansen, Jens B Johansen, Jens C Nielsen, Henning Bundgaard, Henrik K Jensen, Johnni Rudbeck-Resdal, Morten K Christiansen, Jens B Johansen, Jens C Nielsen, Henning Bundgaard, Henrik K Jensen

Abstract

Aims: To describe aetiologies and temporal trends in young patients with atrioventricular block (AVB).

Methods and results: We identified all patients in Denmark, receiving their first pacemaker because of AVB before the age of 50 years between 1996 and 2015. Medical records were reviewed and clinical information and diagnostic work-up results were obtained to evaluate the aetiology. We used Poisson regression testing for temporal trends. One thousand and twenty-seven patients were identified, median age at time of implantation was 38 (interquartile range 25-45) years, 584 (56.9%) were male. The aetiologies were complications to cardiac surgery [n = 157 (15.3%)], congenital AVB [n = 93 (9.0%)], cardioinhibitory reflex [n = 52 (5.0%)], congenital heart disease [n = 43 (4.2%)], complication to radiofrequency ablation [n = 35 (3.4%)], cardiomyopathy [n = 31 (3.0%)], endocarditis [n = 18 (1.7%)], muscular dystrophy [n = 14 (1.4%)], ischaemic heart disease [n = 14 (1.4%)], sarcoidosis [n = 11 (1.1%)], borreliosis [n = 9 (0.9%)], hereditary [n = 6 (0.6%)], side-effect to antiarrhythmics [n = 6 (0.6%)], planned His-ablation [n = 5 (0.5%)], complication to alcohol septal ablation [n = 5 (0.5%)], and other known aetiologies [n = 11 (1.1%)]. The aetiology remained unknown in 517 (50.3%) cases. While the number of patients with unknown aetiology increased during the study period (P < 0.001), we observed no significant change in the number of patients with identified aetiology (P = 0.35).

Conclusion: In a nationwide cohort, the aetiology of AVB was identified in only half the patients younger than 50 years referred for first-time pacemaker implantation. The number of patients with unknown aetiology increased during the study period. These findings indicate need for better insight into aetiologies of AVB and improved diagnostic work-up guidelines.

Keywords: Aetiology; Atrioventricular block; Congenital heart block; Pacemaker; Surgical complication; Temporal trends.

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.

Figures

Figure 1
Figure 1
Flowchart for inclusion of patients with atrioventricular block treated with pacemaker implantation before the age of 50 years.
Figure 2
Figure 2
Identified aetiologies of AV block in patients n = 1027). aAmyloidosis (n = 2), myocarditis (n = 2), severe right ventricular dilation (n = 2), cardiac tumour (n = 1), Kearn–Sayre syndrome (n = 1), rheumatic fever (n = 1), side-effect to radiation therapy (n = 1), and graft vs. host reaction (n = 1). AV, atrioventricular.
Figure 3
Figure 3
Total number of first-time pacemaker implantations in the period from 1 January 1996 and 31 December 2015 in patients

Figure 4

Number of first-time pacemaker implantations…

Figure 4

Number of first-time pacemaker implantations in younger patients with atrioventricular block per year…

Figure 4
Number of first-time pacemaker implantations in younger patients with atrioventricular block per year from 1 January 1996 and 31 December 2015.

Figure 5

Indications of first-time pacemaker implantation…

Figure 5

Indications of first-time pacemaker implantation in younger patients with atrioventricular block (AVB) of…

Figure 5
Indications of first-time pacemaker implantation in younger patients with atrioventricular block (AVB) of known and unknown aetiology in the period from 1 January 1996 and 31 December 2015.
Figure 4
Figure 4
Number of first-time pacemaker implantations in younger patients with atrioventricular block per year from 1 January 1996 and 31 December 2015.
Figure 5
Figure 5
Indications of first-time pacemaker implantation in younger patients with atrioventricular block (AVB) of known and unknown aetiology in the period from 1 January 1996 and 31 December 2015.

References

    1. Danish Pacemaker and ICD Register. Danish Pacemaker and ICD Register Annual report 2015. (21 January 2019, date last accessed).
    1. Zoob M, Smith KS.. The aetiology of complete heart-block. Br Med J 1963;2:1149–53.
    1. Lenegre J. Etiology and pathology of bilateral bundle branch block in relation to complete heart block. Prog Cardiovasc Dis 1964;6:409–44.
    1. Udo EO, van Hemel NM, Zuithoff NP, Doevendans PA, Moons KG.. Prognosis of the bradycardia pacemaker recipient assessed at first implantation: a nationwide cohort study. Heart 2013;99:1573–8.
    1. van Rijsingen IA, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, van der Kooi AJ. et al. Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers: a European Cohort Study. J Am Coll Cardiol 2012;59:493–500.
    1. Anselme F, Moubarak G, Savoure A, Godin B, Borz B, Drouin-Garraud V. et al. Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders. Heart Rhythm 2013;10:1492–8.
    1. Kumar S, Baldinger SH, Gandjbakhch E, Maury P, Sellal JM, Androulakis AF. et al. Long-term arrhythmic and nonarrhythmic outcomes of lamin A/C mutation carriers. J Am Coll Cardiol 2016;68:2299–307.
    1. Moak JP, Barron KS, Hougen TJ, Wiles HB, Balaji S, Sreeram N. et al. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol 2001;37:238–42.
    1. Villain E, Coastedoat-Chalumeau N, Marijon E, Boudjemline Y, Piette JC, Bonnet D.. Presentation and prognosis of complete atrioventricular block in childhood, according to maternal antibody status. J Am Coll Cardiol 2006;48:1682–7.
    1. Kandolin R, Lehtonen J, Kupari M.. Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circ Arrhythm Electrophysiol 2011;4:303–9.
    1. Nery PB, Beanlands RS, Nair GM, Green M, Yang J, McArdle BA. et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol 2014;25:875–81.
    1. Birnie DH, Nery PB, Ha AC, Beanlands RS.. Cardiac sarcoidosis. J Am Coll Cardiol 2016;68:411–21.
    1. Schmidt M, Pedersen L, Sorensen HT.. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 2014;29:541–9.
    1. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA. et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace 2013;15:1070–118.
    1. Carlson SK, Patel AR, Chang PM.. Bradyarrhythmias in congenital heart disease. Card Electrophysiol Clin 2017;9:177–87.
    1. Kasar T, Ayyildiz P, Tunca Sahin G, Ozturk E, Gokalp S, Haydin S. et al. Rhythm disturbances and treatment strategies in children with congenitally corrected transposition of the great arteries. Congenit Heart Dis 2018;13:450–7.
    1. Strauss DG, Selvester RH, Lima JA, Arheden H, Miller JM, Gerstenblith G. et al. ECG quantification of myocardial scar in cardiomyopathy patients with or without conduction defects: correlation with cardiac magnetic resonance and arrhythmogenesis. Circ Arrhythm Electrophysiol 2008;1:327–36.
    1. Groh WJ. Arrhythmias in the muscular dystrophies. Heart Rhythm 2012;9:1890–5.
    1. Brignole M, Deharo JC, De Roy L, Menozzi C, Blommaert D, Dabiri L. et al. Syncope due to idiopathic paroxysmal atrioventricular block: long-term follow-up of a distinct form of atrioventricular block. J Am Coll Cardiol 2011;58:167–73.
    1. Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Muller-Quernheim J.. Sarcoidosis. Lancet 2014;383:1155–67.
    1. Gregoratos G, Cheitlin MD, Conill A, Epstein AE, Fellows C, Ferguson TB Jr. et al. ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). J Am Coll Cardiol 1998;31:1175–209.
    1. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;386:743–800.
    1. Ogunbayo GO, Elayi SC, Ha LD, Olorunfemi O, Elbadawi A, Saheed D. et al. Outcomes of heart block in myocarditis: a review of 31,760 patients. Heart Lung Circ 2019;28:272–6.
    1. Zysko D, Gajek J, Kozluk E, Mazurek W.. Electrocardiographic characteristics of atrioventricular block induced by tilt testing. Europace 2008;11:225–30.
    1. Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A. et al. 2018 ESC guidelines for the diagnosis and management of syncope. Eur Heart J 2018;39:1883–948.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren